Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
– New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib's differentiated clinical profile, including the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies –
Covered in this story
Call it yourself
No calls on $ALMS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alumis Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.